Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Market Cap	2.18B
Revenue (ttm)	1.29B
Net Income (ttm)	19.80M
Shares Out	76.92M
EPS (ttm)	0.39
PE Ratio	73.33
Forward PE	n/a
Dividend	0.19 (0.67%)
Ex-Dividend Date	Jul 24, 2025

Volume	28,930
Average Volume	69,987
Open	28.25
Previous Close	28.20
Day's Range	28.25 - 28.45
52-Week Range	23.50 - 53.10
Beta	0.27
RSI	60.61
Earnings Date	Aug 4, 2025

About TPE:1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, anti-virus, immunomodulating agents, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxant...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1964
• Employees: 198
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1762

Financial Performance

In 2024, TPE:1762's revenue was 1.35 billion, a decrease of -35.42% compared to the previous year's 2.09 billion. Earnings were 53.03 million, a decrease of -79.98%.